The Role of PARP Inhibition in Clinical Practice
The Role of PARP Inhibition in Clinical Practice
Prof. Jonathan A. Ledermann, Dr. Rebecca Dent, Dr. Robert L. Coleman, Prof. Eric Pujade-Lauraine
Accredited e-learning: The Role of PARP inhibition in Clinical Practice
Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)
Dr. Rebecca Dent
Medical Oncologist
National Cancer Center Singapore
Singapore
Dr. Robert L. Coleman
Gynaecologic Oncologist
US Oncology Research
United States (US)
Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France
E-learning | 
60 min
|accreditation:
EACCME |
Sep 2021
I agree that this educational programme:
DNA Damage Response (DDR) and PARP inhibitors are promising but complex therapeutic strategies.
Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive free to access e-learning course. Designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.
This course is endorsed by the Innovative Breast Cancer Research Group (SOLTI), the Gynecological Cancer Group Singapore (GCGS) and the Gynecologic Oncology Trial and Investigation Consortium (GOTIC).
Downloadable slides accompany this e-learning for your own use.
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
Other programmes of interest
60 min
Other programmes developed by Prof. Jonathan A. Ledermann
Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)
Other programmes developed by Dr. Rebecca Dent
Dr. Rebecca Dent
Medical Oncologist
National Cancer Center Singapore
Singapore
Other programmes developed by Prof. Eric Pujade-Lauraine
Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France